Article
Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Oncotarget - 25 Jul 2017
Wang Peng-Fei, Song Hong-Wang, Cai Hong-Qing, Kong Ling-Wei, Yao Kun, Jiang Tao, Li Shou-Wei, Yan Chang-Xiang
Abstract excerpt
Recent studies suggest that inflammation response biomarkers are prognostic indicators of solid tumor outcomes. Here, we quantify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in glioblastomas (GBMs), taking into consideration the role of the isocitrate dehydrogenase (IDH) mutation status. We examined 141 primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
